Marty Makary out as head of US Food and Drug Administration

May 12, 2026

FDA Commissioner Marty Makary is departing after serving just over a year in the position, becoming another senior health official to leave under HHS Secretary Robert F. Kennedy Jr. 's leadership.

Who is affected

Marty Makary (outgoing FDA Commissioner)
Kyle Diamantas (deputy commissioner taking over as acting FDA head)
President Donald Trump and his administration
HHS Secretary Robert F. Kennedy Jr.
FDA staff and scientists
Pharmaceutical companies (facing increased drug rejections)
Health advocates concerned about vaping
Susan B Anthony Pro-Life America (anti-abortion nonprofit)
Former HHS Deputy Secretary Jim O'Neill and former CDC head Susan Monarez (previously departed officials)

What action is being taken

Kyle Diamantas is taking over the FDA Commissioner role in an acting capacity
The administration is searching for a permanent replacement for Makary
President Trump is conducting a state visit to China

Why it matters

This departure represents significant turnover in America's top health leadership positions, particularly under HHS Secretary Kennedy's tenure, which could affect continuity in drug approval processes and public health policy implementation. The FDA Commissioner position is critical as it oversees the safety and efficacy of prescription drugs, medical devices, and tobacco products affecting millions of Americans. Makary's exit amid internal conflicts over politically sensitive issues like flavored vapes and abortion pills highlights tensions between scientific regulatory processes and political pressures within the administration.

What's next

The role will be filled by deputy commissioner Kyle Diamantas on an acting basis until President Trump selects and confirms a permanent replacement for the FDA Commissioner position.

Read full article from source: BBC